The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 |
doi: 10.3389/fphar.2025.1521068
This article is part of the Research Topic New Analytical Technology and Method in Systems Pharmacology View all 5 articles
High-Performance PBPK Model for Predicting CYP3A4 Induction-Mediated Drug Interactions: A Refined and Validated Approach
Provisionally accepted- 1 Tongren Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
- 2 Shanghai PharmoGo Co., Ltd., Shanghai, China
- 3 Zhengzhou Orthopedics Hospital, Zhengzhou, Henan Province, China
- 4 First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
- 5 GenFleet Therapeutics, Shanghai, China
AUCR, the ratio of area under the concentration-time curve of victim after co-administration with rifampicin over area under the concentration-time curve of victim with dosing alone; CmaxR, the ratio of victim Cmax after co-administration with rifampicin over victim Cmax with dosing alone; FDA, Food and Drug Administration; fm, the fraction of metabolism; Fa, cumulative intestinal absorption, %; Vc, distribution volume in central compartment; K12, transfer rate constant from central compartment to peripheral compartment; PC1, peripheral compartment 1; PC2, peripheral compartment 2The authors thank Simulations Plus, Inc. (Lancaster, CA, USA) for authorizing the use of the optimization module in this study.
Keywords: Drug Interactions, rifampicin, CYP3A enzyme, PBPK, pharmacokinetics
Received: 01 Nov 2024; Accepted: 06 Feb 2025.
Copyright: © 2025 Yang, Chen, Si, Wang, Hong-Can and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Tao Chen, Shanghai PharmoGo Co., Ltd., Shanghai, China
Wenteng Si, Zhengzhou Orthopedics Hospital, Zhengzhou, Henan Province, China
An-Hai Wang, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China
Ren Hong-Can, GenFleet Therapeutics, Shanghai, China
Li Wang, GenFleet Therapeutics, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.